APA način citiranja

Karam, I., & Melosky, B. (2012). Response to second-line erlotinib in an EGFR mutation-negative patient with non-small-cell lung cancer: Make no assumptions. Multimed Inc.

Čikaški stil citiranja

Karam, I., i B. Melosky. Response to Second-line Erlotinib in an EGFR Mutation-negative Patient With Non-small-cell Lung Cancer: Make No Assumptions. Multimed Inc, 2012.

MLA način citiranja

Karam, I., i B. Melosky. Response to Second-line Erlotinib in an EGFR Mutation-negative Patient With Non-small-cell Lung Cancer: Make No Assumptions. Multimed Inc, 2012.